KCM
Kynam Capital Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $124M | Sell |
6,100,729
-399,271
| -6% | -$8.13M | 13.37% | 1 |
|
|
2025
Q1 | $118M | Buy |
6,500,000
+1,435,793
| +28% | +$26.1M | 9.91% | 3 |
|
|
2024
Q4 | $128M | Buy |
5,064,207
+1,605,598
| +46% | +$40.6M | 7.56% | 3 |
|
|
2024
Q3 | $118M | Buy |
3,458,609
+69,642
| +2% | +$2.37M | 9.01% | 3 |
|
|
2024
Q2 | $125M | Buy |
3,388,967
+488,967
| +17% | +$18.1M | 9.67% | 2 |
|
|
2024
Q1 | $122M | Sell |
2,900,000
-105,904
| -4% | -$4.44M | 12.74% | 3 |
|
|
2023
Q4 | $119M | Sell |
3,005,904
-194,096
| -6% | -$7.7M | 13.21% | 3 |
|
|
2023
Q3 | $88.1M | Buy |
3,200,000
+600,000
| +23% | +$16.5M | 14.4% | 2 |
|
|
2023
Q2 | $88.2M | Buy |
2,600,000
+1,190,549
| +84% | +$40.4M | 12.13% | 2 |
|
|
2023
Q1 | $50.7M | Sell |
1,409,451
-195,939
| -12% | -$7.05M | 6.55% | 4 |
|
|
2022
Q4 | $71.6M | Buy |
1,605,390
+5,263
| +0.3% | +$235K | 10.98% | 3 |
|
|
2022
Q3 | $45M | Buy |
1,600,127
+467,868
| +41% | +$13.2M | 9.48% | 3 |
|
|
2022
Q2 | $30.5M | Buy |
1,132,259
+379,225
| +50% | +$10.2M | 7.8% | 4 |
|
|
2022
Q1 | $25.6M | Buy |
753,034
+526,308
| +232% | +$17.9M | 8.32% | 4 |
|
|
2021
Q4 | $8.76M | Buy |
+226,726
| New | +$8.76M | 4.68% | 6 |
|